Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...

Applied Therapeutics APLT announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application ...

Applied Therapeutics shares (NASDAQ:APLT) were down 75% early Friday, the first trading session after the company announced ...

Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...

Investing.com -- RBC Capital Markets downgraded Applied Therapeutics Inc (NASDAQ:APLT) stock to "sector perform" from "outperform” citing increased risks after the U.S. Food and Drug ...

Applied Therapeutics ( APLT, Financials) announced that the U.S. Food and Drug Administration issued a Complete Response ...

Baird analyst Brian Skorney lowered the firm’s price target on Applied Therapeutics (APLT) to $5 from $14 and keeps an Outperform rating on the ...

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...

Citi raised the firm’s price target on Applied Therapeutics (APLT) to $13 from $11 and keeps a Buy rating on the shares after having updated ...

FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for ...

On Friday, Applied Therapeutics Inc (APLT) stock saw a modest uptick, ending the day at $9.62 which represents a slight increase of $0.35 or 3.78% from the prior close of $9.27. The stock opened at $9 ...

Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that ...